Monsanto Company announced last week that it has advanced its higher yielding soybean trait, sourced from Mendel Biotechnology Inc., into its Phase III development stage.
The technology was identified and developed through a research program funded by Monsanto, designed to leverage Mendel's expertise in regulatory pathways and network biology. The two companies have worked together for over a decade on the development of biotechnology-based traits for Monsanto's row crops seed business, and the companies continue to collaborate to develop high-value traits.
"We are delighted that one of our traits has reached this advanced stage in Monsanto's commercial pipeline, which underscores the commercial viability and success of this project, and validates our long term R&D strategy focused on understanding gene networks that control important plant traits," said Neal Gutterson, President and Chief Executive Officer of Mendel. "Monsanto is the acknowledged global leader in the development and commercialization of high-value, sustainable agricultural seed products. We are very excited to be a developer and provider of trait technologies for them."
"Monsanto is committed to providing farmers with higher grain yields to help support the world's growing demand for food, feed and fuel," said Steve Padgette, Vice President of Biotechnology at Monsanto. "We are extremely pleased to see our long-term, valued collaboration with Mendel deliver an important trait into Phase III advanced commercial development."
Higher yielding soybeans, which have demonstrated 6 percent to 7 percent yield increase across three seasons of testing in 56 field environments, are expected to be an important part of our stacked soybean trait portfolio of the future, Padgette said.
"We also are excited about other Mendel genes being evaluated in our R&D pipeline," he said.